Ignyte Acquisition (NASDAQ:IGNY – Get Rating) and Inhibikase Therapeutics (NYSE:IKT – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
Earnings & Valuation
This table compares Ignyte Acquisition and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.
Get Ignyte Acquisition alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ignyte Acquisition | N/A | N/A | -$490,000.00 | N/A | N/A |
| Inhibikase Therapeutics | $3.10 million | 7.36 | -$14.79 million | ($0.74) | -1.22 |
Ignyte Acquisition has higher earnings, but lower revenue than Inhibikase Therapeutics.
Insider and Institutional Ownership
61.1% of Ignyte Acquisition shares are owned by institutional investors. Comparatively, 13.3% of Inhibikase Therapeutics shares are owned by institutional investors. 55.8% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.Risk & Volatility
Ignyte Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Ignyte Acquisition and Inhibikase Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ignyte Acquisition | 0 | 0 | 0 | 0 | N/A |
| Inhibikase Therapeutics | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Ignyte Acquisition and Inhibikase Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ignyte Acquisition | N/A | 365.46% | -0.83% |
| Inhibikase Therapeutics | -4,894.27% | -48.78% | -44.49% |
Summary
Ignyte Acquisition beats Inhibikase Therapeutics on 5 of the 8 factors compared between the two stocks.
About Ignyte Acquisition
(Get Rating)
Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company intends to focus on target businesses in the life sciences, biotechnology, and healthcare sectors. Ignyte Acquisition Corp. was incorporated in 2020 and is based in New York, New York.
About Inhibikase Therapeutics
(Get Rating)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Ignyte Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyte Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.